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Abstract 
Background: The COVID-19 pandemic has affected the world extraordinarily. This disease has a potential to cause a 
significantly severe course of disease leading to respiratory complications, multiple organ failure and possibly death. 
In the fight against this pandemic-causing disease, medical professionals around the world are searching for phar-
macological agents that could treat and prevent disease progression and mortality. To speed the search of promising 
treatment options, already existing pharmacological agents are repurposed for the potential treatment of COVID-19 
and tested in clinical trials. The aim of this literature review is to investigate the efficacy and safety of repurposed 
pharmacological agents for the treatment of COVID-19 at different pathophysiologic stages of the disease. For this 
literature review, online-databases PubMed and Google Scholar were utilised. Keywords “COVID-19”, “SARS-CoV-2”, 
“pathogenesis”, “drug targets”, “pharmacological treatment”, “cytokine storm”, “coagulopathy” and individual drug names 
were used. Scientific articles, including reviews, clinical trials, and observational cohorts, were collected and analysed. 
Furthermore, these articles were examined for references to find more clinical trials testing for the potential treatment 
of COVID-19. In total, 97 references were used to conduct this research paper.
Results: The most beneficial pharmacological agent for the treatment of COVID-19 are corticosteroids, especially 
dexamethasone, for the treatment of mechanically ventilated COVID-19 patients. Other promising agents are rem-
desivir for the treatment of patients with COVID-19 pneumonia requiring minimal supplemental oxygen therapy, 
and IL-6 receptor antagonist monoclonal antibodies in severe COVID-19. Lopinavir/ritonavir, as well as chloroquine or 
hydroxychloroquine with or without azithromycin demonstrate the least efficacy in the treatment of COVID-19. The 
clinical benefits of the treatment of a COVID-19-specific coagulopathy with increased dosing of anticoagulation need 
further research and confirmation of randomised controlled trials.
Conclusion: The search for pharmacological treatment of COVID-19 has elicited great controversy. Whereas drugs 
like chloroquine, hydroxychloroquine, and lopinavir/ritonavir have not shown proven benefit, the agents remdesivir 
and dexamethasone are recommended for clinical use for the treatment of COVID-19. Further randomised trials for 
other pharmacological treatment strategies are awaited.
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Tocilizumab, Corticosteroids, Anticoagulation
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Background
The new strain of coronavirus, termed severe acute res-
piratory syndrome coronavirus two (SARS-CoV-2), has 
caused numerous cases of a respiratory illness, named 
Coronavirus disease 2019 (COVID-19), leading to a 
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rapid spread of the disease [1]. On the 11th of March 
2020, the World Health Organization (WHO) declared 
COVID-19 a pandemic [2]. Since then, COVID-19 has 
changed the world immensely and has taken a toll on 
healthcare systems. As of the 11th of March 2021, glob-
ally there has been over 117 million confirmed cases 
of COVID-19 of which over 2.6 million cases have 
resulted death [3]. COVID-19 has affected some coun-
tries worse than others leading to higher case fatalities 
when hospitals and intensive care units (ICU) could 
not carry the burden of this disease and shortages of 
medical equipment and ventilation systems became 
inevitable. As this disease has already claimed a vast 
number of lives, it has become an urgent task to evalu-
ate potential pharmacological agents for the treatment 
of COVID-19 to improve clinical outcomes, decrease 
case fatalities, and contain the spread of the disease.
To speed the search of promising treatment and 
decrease the devastating effect of this potentially 
deadly disease, many clinical trials around the world 
are engaged in repurposing already existing drugs that 
had been developed for other indications and test them 
for the efficacy and safety in COVID-19.
The aim of this literature review is to investigate 
the efficacy and safety of repurposed pharmacologi-
cal agents for the treatment of COVID-19 at different 
pathophysiologic stages of the disease.
For this literature review, online-databases PubMed 
and Google Scholar were utilised. Keywords “COVID-
19”, “SARS-CoV-2”, “pathogenesis”, “drug targets”, 
“pharmacological treatment”, “cytokine storm”, “coagu-
lopathy” and individual drug names were used. Sci-
entific articles, including reviews, clinical trials, and 
observational cohorts, were collected and analysed. 
Furthermore, these articles were examined for refer-
ences to find more clinical trials testing for the poten-
tial treatment of COVID-19. In total, 97 references 
were used to conduct this research paper.
This literature review focuses on pharmacological 
agents that have promising features for the treatment 
of COVID-19. These agents are organised according to 
their mechanism of action and hypothesised activity 
against SARS-CoV-2 and its sequelae. The first chapter 
is dedicated to the characteristics of SARS-CoV-2 and 
its pathogenic actions to illuminate possible important 
drug targets. Thereafter, drugs with hypothetical anti-
viral properties, including chloroquine and hydroxy-
chloroquine with and without azithromycin, lopinavir/
ritonavir, and remdesivir, drugs with immunomodula-
tory properties, tocilizumab and corticosteroids, as 
well as anticoagulants are analysed for the potential use 
of clinical treatment of COVID-19.
SARS‑COV‑2
SARS-CoV-2, which was initially called 2019-nCoV, is 
the third coronavirus causing severe respiratory infec-
tions in humans in the past 20  years after severe acute 
respiratory syndrome coronavirus (SARS-CoV), leading 
to the SARS epidemic from 2003, and Middle East res-
piratory syndrome coronavirus (MERS-CoV), leading to 
the MERS epidemic from 2012. All three of these viruses 
belong to the genus of Betacoronavirus [4]. SARS-
CoV-2, as all the members of the Coronaviridae family, 
is an enveloped positive sense, single-stranded ribonu-
cleic acid (RNA) virus that shares a genome similarity 
of 79% with SARS-CoV and 50% with MERS-CoV [5]. 
Further genome sequencing demonstrated a similarity 
of 96.2% with a bat coronavirus, BatCoV RaTG13, indi-
cating that bats may be the original hosts from which 
SARS-CoV-2 has emerged [6]. SARS-CoV and MERS-
CoV both needed mammalian intermediate hosts to be 
able to transmit to humans. Since the close relative of 
SARS-CoV-2 found in bats has significant differences in 
its receptor-binding domain compared to the pandemic-
causing virus, it is thought that SARS-CoV-2 may as well 
have developed necessary mutations within intermediate 
hosts to be able to infect humans [7–9]. Another theory 
suggests a period of cryptic transmissions in which the 
virus gradually mutated within humans and eventually 
acquired the functions to cause a significant disease [8, 
9]. The exact mechanism how SARS-CoV-2 was able to 
affect humans is still unknown, but further research may 
become important to prevent future dangerous zoonotic 
transmissions of infections.
Structure and life cycle
SARS-CoV-2 is characterised by the following structural 
proteins: spike (S), envelope (E), membrane (M), and 
nucleocapsid (N) proteins [10]. Angiotensin-converting 
enzyme two (ACE2) has been confirmed to be the recep-
tor that facilitates SARS-CoV-2 entry into the host cells 
[6, 11]. ACE2 is specifically expressed on the surface of 
lung alveolar and small intestine epithelial cells, but also 
on vascular endothelial cells, smooth muscle cells, oral 
and nasal mucosa, and in kidneys and heart [12]. SARS-
CoV-2 is thought to enter its target cell via endocytosis 
and via membrane fusion. The S protein of SARS-CoV-2 
consist of subunits, S1 and S2. The S1 subunit contains 
the receptor-binding domain which binds to ACE2 for 
entry. The S2 subunit facilitates the fusion of the viral 
envelope with the host cell’s membrane. For the activa-
tion of these subunits, priming of the S protein by host 
cell surface proteases must occur. Transmembrane pro-
tease serine subtype two (TMPRSS2) cleaves the S pro-
tein at its S1/S2 and S2’ cleavage sites [13]. After this, the 
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process of host cell entry can begin. The viral positive 
sense RNA is being uncoated and released into the host 
cell cytoplasm. Translation using host ribosomes pro-
ceeds and polyproteins are encoded [10]. The polypro-
teins are proteolysed to 16 non-structural proteins that 
are involved in replication and transcription, including 
viral proteases 3-chymotrypsin-like protease (3CLpro), 
also called main protease, and papain-like protease 
(PLpro), and RNA-dependent RNA polymerase (RdRp) 
[14]. RdRp replicates the positive sense to a negative 
sense RNA. This can be used in two ways. First, it can be 
used for the replication for more genomic positive sense 
RNA that will be facilitated in new virions. Second, it can 
be transcribed to subgenomic messenger RNAs via dis-
continuous transcription that encode for all viral struc-
tural proteins, S, E, M, and N. The structural proteins are 
encoded at the rough endoplasmic reticulum and trans-
ported further to the Golgi apparatus where assembly of 
the positive sense RNA and structural proteins continues 
to produce new virions. Finally, mature virions are trans-
ported within Golgi vesicles and released out of the host 
cell via exocytosis [14, 15].
Pathogenesis and clinical course
COVID-19 most commonly presents at onset with fever, 
cough, myalgia, fatigue, and headache. As the disease 
progresses, dyspnoea and lymphopenia become promi-
nent features in susceptible individuals that develop 
viral pneumonia [16–18]. Typical computed tomog-
raphy (CT) findings in these with viral pneumonia are 
bilateral, mostly peripheral ground glass opacities, com-
monly mixed with consolidations, primarily in the lower 
lobes [19]. Complications can be severe, leading to mul-
tiple organ failure and death, and include acute respira-
tory distress syndrome (ARDS), acute cardiac injury, 
thromboembolic disturbances, secondary infections, 
shock, and inflammatory complications, such as cytokine 
release syndrome (CRS) or, also called, cytokine storm 
[16, 20]. CRS is an excessive uncontrolled cascade of pro-
inflammatory cytokine and chemokine release, including 
the release of interleukin 6 (IL-6) [21].
Severe COVID-19 patients have higher risk of throm-
bosis. A reason for that is the disrupted alveolar-
endothelial barrier leading to endothelial dysfunction 
and promotion of microcirculatory microthrombi [22]. 
ACE2 is also well expressed on endothelial cells [12]. 
When SARS-CoV-2 infects endothelial cells, the process 
will promote further endothelial damage and inflamma-
tion advocating a coagulation cascade. Thromboembolic 
complications are also aggravated by the cytokine storm, 
systemic inflammatory response syndrome (SIRS), and 
possible immobilisation and comorbidities of the patients 
[23].
Potential drug targets
The pathogenetic processes occurring in the COVID-19 
infection give rise to several potential drug targets. The 
first process that can be targeted is the viral entry and 
endocytosis of SARS-CoV-2 into the host cells. Chloro-
quine and hydroxychloroquine are drugs that are hypoth-
esised to act against SARS-CoV-2 by inhibiting virus-host 
fusion [24]. Viral proteases are also important drug tar-
gets. SARS-CoV-2 encodes viral proteases 3CLpro and 
PLpro during its life cycle which are important for rep-
lication. Lopinavir/ritonavir is a drug combination pri-
marily used against HIV which acts as a viral protease 
inhibitor. By inhibiting 3CLpro and PLpro, lopinavir/rito-
navir could possibly stop viral replication [14, 24]. Essen-
tial for viral replication of SARS-CoV-2 is also the RdRp. 
Inhibiting this non-structural protein will bring the rep-
lication process of this virus to a standstill. A promising 
RNA polymerase inhibitor in the fight against COVID-19 
is remdesivir [14, 25].
The cytokine storm is also an important pathogenic 
process of COVID-19 with devastating sequelae. There-
fore, pharmacological agents with immunomodulatory 
effects are important to consider in the treatment of 
COVID-19. Promising immunomodulatory therapy strat-
egies for COVID-19 include specific immunosuppression 
by the inhibition of IL-6 signal transduction with the 
use of tocilizumab and non-specific immunosuppressive 
strategies including corticosteroids [26].
Pharmacological agents with antiviral properties
Chloroquine and hydroxychloroquine with or without 
azithromycin
Chloroquine and its derivative, hydroxychloroquine, 
are 4-aminoquinolines that have been widely used in 
the prophylaxis and treatment of malaria. Besides their 
antimalarial activity, they also exert anti-inflammatory 
action. Thus, hydroxychloroquine is also frequently used 
in the treatment of rheumatic diseases, such as rheuma-
toid arthritis and systemic lupus erythematosus [27]. The 
broad antiviral properties of chloroquine and its deriva-
tive have also been recognised. In the fight against SARS-
CoV-2, they are thought to inhibit viral entry and release 
from host cells by increasing the pH in endosomes, lys-
osomes, and Golgi vesicles. Endocytosis is also thought 
to be prevented by the inhibition of ACE2 glycosylation. 
Furthermore, they have promising anti-inflammatory 
effects that could potentially combat a cytokine storm by 
acting against the release of inflammatory markers [14].
Chloroquine had already shown potential in the treat-
ment and prophylaxis of SARS, as it successfully inhibited 
in vitro infection and spread of SARS-CoV in two sepa-
rate studies [28, 29]. Chloroquine has also demonstrated 
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to be effective against SARS-CoV-2 in  vitro. A study 
conducted by Wang and colleagues proved that chloro-
quine could inhibit SARS-CoV-2 infection at entry and 
post-entry stages in Vero E6 cells and advocated the run 
of clinical trials for chloroquine against COVID-19 [30]. 
Yao and colleagues confirmed identical findings by test-
ing chloroquine, but also hydroxychloroquine, in vitro in 
Vero cells against SARS-CoV-2. Furthermore, they impli-
cated that hydroxychloroquine had even more potency 
in comparison to chloroquine in in vitro activity against 
the COVID-19-causing virus [31]. Liu and colleagues 
as well performed in  vitro analyses of chloroquine and 
hydroxychloroquine in African green monkey kidney 
VeroE6 cells in relation to SARS-CoV-2 infection. They 
concluded that hydroxychloroquine, being less toxic than 
chloroquine, could competently inhibit infection but they 
warned for extensive use and dosing, as this could lead to 
dangerous poisoning [32].
A Brazilian double-blinded, phase IIb, randomised 
clinical trial tested for the efficacy and safety of chlo-
roquine diphosphate in severe SARS-CoV-2 infected 
patients with two different dosages. 81 participants were 
enrolled in this study, in which 41 received high-dose 
chloroquine diphosphate 600 mg twice a day for 10 days 
and 40 received low-dose chloroquine diphosphate 
450  mg twice a day on the first day and once a day for 
4 days. 100% of the participants received azithromycin, 
whereas 86.8% in the low-dose and 92.5% in the high-
dose group also received oseltamivir simultaneously to 
exclude other infections. The study concluded higher 
lethality in the high-dose group with 39% compared to 
the low-dose group with 15%. Therefore, high dose treat-
ment in severe COVID-19 patients was discontinued as 
the risks were higher than the benefits. These findings 
could have been influenced by the concurrent adminis-
tration of azithromycin and oseltamivir. Also, the ran-
domisation of this study lead to the assignment of more 
of older patients with cardiac comorbidities to the high-
dose group which could have also affected the results. 
On the other hand, typical severe COVID-19 patients are 
individuals with higher age and comorbidities, thus, the 
study excluded the general use of high-dose chloroquine 
for severe COVID-19 patients. Furthermore, in neither 
group viral clearance by day four was attained. This study 
did not conclude any benefits of chloroquine diphosphate 
in severe COVID-19 patients, but they suggested further 
testing of chloroquine as a prophylactic drug and its use 
in mild to moderate COVID-19 patients [33] (Table 1).
Another randomised study conducted in China tested 
for the efficacy and safety of chloroquine in COVID-19 
patients in comparison to the use of lopinavir/ritonavir. 
They reported that chloroquine was superior in viral 
clearance with 100% clearance by day 13 versus 91.7% 
by day 14 of the control group, lung improvement on CT 
with 100% clearance in comparison to 75% of the con-
trol group by day 14, and earlier hospital discharge with 
100% versus only 50% of the lopinavir/ritonavir group at 
day 14. This study was heavily limited by the small sam-
ple size of only 22 participants. 10 participants, three of 
which were in severe and seven in moderate condition, 
were in the chloroquine and 12, five of which with severe 
and seven with moderate disease, in the lopinavir/rito-
navir group [34] (Table 1). Similar results of chloroquine 
being potent against COVID-19 were reported as studies 
including more than 100 patients in more than 10 hos-
pitals throughout China concluded superiority against 
control treatment. This led to the recommendation of 
chloroquine for the treatment of pneumonia caused by 
COVID-19 for larger populations [35]. The details of the 
studies were not mentioned which may raise questions to 
the accuracy of this proposition.
The efficacy and safety of hydroxychloroquine against 
COVID-19 was analysed in a randomised controlled trial 
organised in three Chinese provinces. Of 150 partici-
pants hospitalised for COVID-19, 75 received standard 
care of intravenous fluids, supplemental oxygen, regu-
lar laboratory, and SARS-CoV-2 testing, monitoring of 
haemodynamic stability, and intensive care, whereas 75 
participants received standard care in addition to hydrox-
ychloroquine, 1200 mg daily for 3 days, then 800 mg daily 
for a total of 2 weeks, or 3 weeks for severe patients. 
Most of the participants had mild to moderate symptoms 
and two had severe COVID-19. The mean time between 
onset of symptoms and randomisation was 16.6  days. 
This study concluded no significant differences in nega-
tive viral conversion of the hydroxychloroquine group 
compared to the control group. Two patients in total, 
both from the chloroquine group, experienced serious 
side events with disease progression and upper respira-
tory tract infection. More non-serious side events, such 
as gastrointestinal symptoms, were also experienced in 
the hydroxychloroquine group [36] (Table 1). This study 
is limited as it is not double-blinded and because the time 
between disease onset to randomisation is extensively 
long. Nevertheless, a treatment addition of hydroxychlo-
roquine to standard care of persistent mild to moderate 
COVID-19 infection was not recommended.
An observational cohort study operated in New York 
City concentrated on the correlation of the use of hydrox-
ychloroquine and intubation or death in SARS-CoV-2 
positive, hospitalised patients. In this analysis, 1376 
patients were included. 811 of these received hydroxy-
chloroquine 600 mg on the first day, followed by 400 mg 
daily for 4 days. 565 patients did not receive hydroxy-
chloroquine. Treatment started for 45.8% of the hydroxy-
chloroquine group within 24 h and for 85.9% within 48 h 
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from the presentation to the emergency department. The 
patients were observed for a median time of 22.5  days. 
This study did not conclude any significant differences 
between the groups for the risk of intubation or death 
[37] (Table 1).
In France, Gautret and colleagues investigated the 
effect of hydroxychloroquine on the nasopharyngeal viral 
load of COVID-19 hospitalised patients in an open-label, 
non-randomised clinical trial. Out of 36 evaluated partic-
ipants, 20 were treated with oral hydroxychloroquine sul-
phate 200 mg three times a day for 10 days, six of which 
additionally received azithromycin 500  mg on the first 
day, then 250  mg per day for 4 days. The remaining 16 
patients were in the control group. After 6 days, of the 
patients treated with hydroxychloroquine and azithro-
mycin 100% were virologically negative in comparison 
to 57.1% of the hydroxychloroquine and 12.5% of the 
control group. They concluded that hydroxychloroquine 
was efficient in reducing viral load of SARS-CoV-2 with 
azithromycin enhancing this result and recommended 
the use of this combination for COVID-19 treatment 
and reduction of transmission [38] (Table  1). However, 
this study has been criticised to be methodologically 
flawed and “non-informative” by reviewers [39, 40]. On 
the basis of the aforementioned results, Molina and col-
leagues conducted a prospective observational study in 
which they examined virologic and clinical outcomes in 
11 hospitalised severe COVID-19 patients treated with 
hydroxychloroquine and azithromycin in the same dose 
regime. They contradicted the results of Gautret and col-
leagues as none of their patients had virological clearance 
after 6 days of treatment. Of these patients, one had died, 
two needed ICU transfer, and one had to discontinue the 
combination treatment because of QT interval prolonga-
tion on ECG. Therefore, they established that there is no 
strong evidence that supports hydroxychloroquine and 
azithromycin in combination for the treatment of severe 
COVID-19 patients [41] (Table 1).
Another study evaluated the efficacy and safety of 
hydroxychloroquine and azithromycin for COVID-19 
treatment. In this multicentre, randomised, open-label, 
controlled trial, 665 hospitalised patients with confirmed 
and suspected mild to moderate COVID-19 were divided 
into three groups. The first group with 227 participants 
received standard care. The standard care was decided 
by the clinicians and the use of glucocorticoids, immu-
nomodulators, antibiotics, and antivirals was permitted. 
The second group with 221 participants received stand-
ard care and hydroxychloroquine 400  mg two times 
a day for 7 days. The third group with 217 participants 
additionally received azithromycin 500  mg once a day 
for 7 days. 504 participants had confirmed COVID-19, 
87.8% were enrolled in the study within 10  days, with 
a median time of 7 days of the onset of symptoms, and 
all participants received either no supplemental oxygen 
or maximally 4 l per minute. After 15 days of treatment, 
the clinical status was assessed using a seven-point ordi-
nal scale. The study concluded no difference between 
the groups regarding the clinical improvement of the 
patients. In the second and third group, the frequency of 
corrected QT interval (QTc) prolongation and increased 
liver enzymes were higher [42] (Table 1).
If hydroxychloroquine had potential for the postexpo-
sure prophylaxis for COVID-19 was inspected in a dou-
ble-blinded, randomised, placebo-controlled clinical trial 
in the United States and Canada. Recruitment of partici-
pants was conducted via online surveys to reach as many 
candidates as possible. 821 participants were enrolled in 
this study. All of them were asymptomatic and had either 
high-risk or moderate-risk exposure to COVID-19. Expo-
sure was defined as household or occupational contact 
less than six feet to a COVID-19-infected individual for 
more than 10 min with neither face mask or eye shield, 
accounting for high-risk, or with face mask but no eye 
shield, being moderate-risk exposure. High-risk exposure 
candidates considered for 87.6% of all participants. Ran-
domisation occurred 4 days after exposure. 414 partici-
pants received hydroxychloroquine in a loading dosage of 
800 mg, with subsequent 600 mg after 6 to 8 h, followed 
by 600 mg once a day for 4 days. 407 participants received 
a placebo. The participants were contacted after 1, 5, 10, 
and 14  days to evaluate their health status with follow-
up surveys. Due to lack of diagnostic tests, not all partici-
pants were able to get polymerase chain reaction (PCR) 
tests for SARS-CoV-2. After 14  days, 107 participants, 
counting 13.0% of all recruited, had PCR-confirmed or 
probable COVID-19 with symptoms compatible with the 
disease. Of these, 49, or 11.8%, of the participants were 
in the hydroxychloroquine group, and 58, or 14.3%, were 
in the placebo group. The difference between the groups 
in disease incidence was not significantly different. Also, 
the hydroxychloroquine group experienced more side 
effects by day 5 in comparison to the placebo group, the 
first accounting for 40.1% and the latter for 16.8%. These 
side effects included gastrointestinal disturbances, such 
as nausea, abdominal discomfort, and loose stools [43] 
(Table 1). However, this study has its limitations. Because 
of the internet-based fashion of this study, mostly 
younger, healthier individuals were recruited. That is why 
this study cannot exclude the efficacy of hydroxychloro-
quine for postexposure prophylaxis in more susceptible 
individuals, such as people with older age or with comor-
bidities. Also, due to lack of testing possible asympto-
matic COVID-19 carriers could not be fully detected. On 
the other hand, most of the participants were health care 
workers. As these individuals are the ones with higher 
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exposure risk to sick people, the search for possible 
COVID-19 prophylaxis to decrease healthcare burden, 
and the fact that this study did not conclude a significant 
benefit for this group by taking hydroxychloroquine to 
prevent COVID-19, is very important.
As a response to more and more clinical trials involved 
in the use of hydroxychloroquine for COVID-19, espe-
cially in combination with azithromycin, the concerns 
about serious side effects, including life-threatening 
rhythmic disturbances, are rising. A retrospective cohort 
study performed in hospitals in the United States and 
Italy focused on this concern. 251 COVID-19 patients 
which were hospitalised and treated with hydroxychlo-
roquine and azithromycin were included. Dosages were 
orally 400  mg twice a day on the first day, followed by 
200  mg twice a day for 4 days for hydroxychloroquine, 
and orally 500 mg of azithromycin once a day for 5 days. 
Mandatory for inclusion was also a baseline ECG and 
a minimum of one follow-up ECG of treatment. The 
results presented a significant correlation between the 
drug treatment and prolongations of QTc. 58 of 251 
patients, accounting for 23%, experienced an extreme 
prolongation of QTc of more than 500  ms with previ-
ous normal QTc on baseline ECG. One patient in this 
group developed a polymorphic ventricular tachycardia, 
characteristic to torsade de point, and needed cardiover-
sion. The measured prolongation also correlated partially 
retrogressively with treatment cessation. The study con-
cluded that the combination of hydroxychloroquine and 
azithromycin for the treatment of COVID-19 expresses 
significant risk for the development of QTc prolongation, 
which in turn increases the risk for the development of 
life-threatening arrythmia and recommends a risk strati-
fication before necessary administration [44] (Table 1).
As different clinical trials are presenting different 
results, the use of chloroquine or hydroxychloroquine 
with or without azithromycin in COVID-19 patients trig-
ger a great controversy. In July 2020, after many clini-
cal trials were already conducted, two research papers 
are presenting results that many clinicians already sus-
pected. Although, chloroquine and hydroxychloroquine 
have presented to be effective in VeroE6 cells of African 
green monkey kidneys, these pharmacological agents 
have shown to not have in  vitro effect on SARS-CoV-
2-infected human airway epithelial cells [45, 46]. The 
researchers oppose that chloroquine and hydroxychlo-
roquine have antiviral effect in the human respiratory 
system. This is explained by the low levels of cysteine 
protease cathepsin L in airway epithelial cells. This endo-
somal enzyme activates the S protein of SARS-CoV-2 for 
viral entry in a pH-dependent pathway. Contrarily, viral 
entry of SARS-CoV-2 in airway epithelial cells appear 
to occur in a pH-independent pathway via TMPRSS2 
[45]. Thus, chloroquine and hydroxychloroquine cannot 
express their pH-modulating effects in inhibiting viral 
entry in human airway epithelial cells. Furthermore, test-
ing of hydroxychloroquine with or without azithromycin 
in SARS-CoV-2-infected macaques presented that the 
drug did not affect levels of viral load nor had treatment 
efficacy in early or late infections, or as post-exposure 
prophylaxis [46].
From the update of the COVID-19 Treatment Guide-
lines of the National Institutes of Health (NIH) from 
October 2020, the use of chloroquine and hydroxychlo-
roquine in hospitalised and non-hospitalised COVID-
19 patients with or without azithromycin, as well as 
the use of high-dose chloroquine for the treatment of 
COVID-19 are not recommended. Exceptions are the 
use of chloroquine or hydroxychloroquine in non-hos-
pitalised patients in clinical trials [47]. This opinion is 
supported by the European Respiratory Society (ERS) 
whose COVID-19 management guideline do not recom-
mend hydroxychloroquine in hospitalised and non-hos-
pitalised patients, azithromycin in hospitalised patients 
in the absence of bacterial infection, nor the combination 
of hydroxychloroquine and azithromycin in COVID-19 
patients [48].
Lopinavir/ritonavir
Lopinavir and ritonavir are antiretroviral agents that 
inhibit viral proteases. Lopinavir is used in combination 
with ritonavir to enhance its effect in the treatment for 
HIV [25]. Lopinavir/ritonavir had previously shown to 
have activity against SARS-CoV in vitro [49]. A consecu-
tive retrospective matched cohort study concluded that 
lopinavir/ritonavir in addition to standard treatment had 
improved the clinical outcomes of SARS patients [50]. In 
the fight against SARS-CoV-2, this drug combination has 
demonstrated efficacy against its 3CLpro on molecular 
level [51]. These findings spark hope in the treatment of 
COVID-19 and led to in vivo studies of lopinavir/ritona-
vir against this disease.
An open-label, randomised, controlled trial in China, 
named LOTUS, assessed the efficacy and safety of lopi-
navir/ritonavir in SARS-CoV2-infected, hospitalised, 
seriously ill patients. Eligible participants were those 
with positive reverse transcription PCR (RT-PCR) test 
for SARS-CoV-2, imaging-confirmed pneumonia, and a 
peripheral capillary oxygen saturation (SpO2) of 94% or 
less. Of 199 enrolled participants, 99 were grouped to 
receive lopinavir/ritonavir 400 mg and 100 mg two times 
a day for 14  days, and 100 participants received stand-
ard care. Five patients of the lopinavir/ritonavir group 
did not receive doses due to early death and the refusal 
of physicians. In median time, participants were ran-
domised after 13 days from the onset of symptoms. The 
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participants were evaluated for clinical improvement, 
viral load, adverse events, and mortality. The median time 
to clinical improvement was 15  days in the lopinavir/
ritonavir group and 16  days in the control group. Also, 
the mortality after 28 days and the nasopharyngeal viral 
load did not differ significantly between the groups with 
19.2% in the lopinavir/ritonavir in comparison to 25% in 
the standard of care group. The lopinavir/ritonavir group 
had more commonly adverse events, being mostly gas-
trointestinal complaints. Serious adverse events, includ-
ing ARDS, acute kidney injury, and secondary infections, 
were more common in the standard care group than in 
the treatment group with 32.3% versus 20% of occur-
rence, respectively. All in all, the study did not conclude 
a significant benefit of lopinavir/ritonavir in compari-
son to standard care in clinical improvement, mortality, 
and decreasing viral load in the treatment of seriously 
ill COVID-19 patients [52] (Table 2). However, since the 
median time for randomisation was relatively long for 
usual antiviral treatment and the participants had more 
severe disease, the study cannot exclude the efficacy of 
this drug combination in earlier administration and in 
milder diseased patients. Also, as the pandemic is having 
a vast impact on the hospital burden around the world, a 
hospital-stay shortened by 1 day could still have benefits 
[53].
120 SARS-CoV-2-positive, non-critically ill, hospital-
ised patients in Wuhan, China were analysed in a ret-
rospective cohort study. A comparison of viral RNA 
shedding was undertaken between patients that received 
lopinavir/ritonavir and those who did not. Further-
more, clinical characteristics and general risk factors for 
prolonged viral shedding, which was defined as more 
than 23  days, was performed. 78 of these 120 patients 
received oral lopinavir/ritonavir 400  mg and 100  mg 
twice a day for a median duration of 10  days. Treat-
ment initiation was performed within a median time 
of 10  days from the onset of symptoms. 54 of the 120 
patients received systemic corticosteroids. In compari-
son to the control group, the lopinavir/ritonavir group 
had shorter time frames of viral shedding with a median 
duration of 22  days versus 28.5  days from the onset of 
symptoms. This shortening was only seen in patients 
who had initiated treatment within 10 days of symptom 
onset. Treatment initiation exceeding 10 days from onset 
of symptoms had no difference in the viral shedding 
median duration from the control group. Furthermore, 
older age of patients was also identified as a risk factor 
for prolonged viral shedding with a median age of 56 for 
prolonged shedding versus 48 for shedding of 23  days 
or shorter. The presence of comorbidities and the use of 
systemic corticosteroids were not associated with pro-
longed shedding. The study concludes that older age and 
the absence of lopinavir/ritonavir treatment were associ-
ated with prolonged viral shedding of SARS-CoV-2 [54] 
(Table 2).
The exploratory, randomised, partially blinded, con-
trolled trial in China, named ELACOI, researched 
the efficacy and safety of lopinavir/ritonavir and, also, 
arbidol, as monotherapies in mild to moderate, hospi-
talised COVID-19 patients. The 86 enrolled participants 
were randomised into three groups. The first group 
included 34 participants and received lopinavir/ritonavir 
200 mg and 50 mg orally twice per day for 7 to 14 days. 
The second group with 35 participants received arbidol, 
a hemagglutinin inhibitor previously known to have 
actions against influenza and SARS in  vitro, in a dos-
age of 200 mg three times per day for 7 to 14 days. And 
the third group with 17 participants did not receive any 
antiviral medications. The different groups had all simi-
lar baseline characteristics with mild to moderate dis-
ease expression of COVID-19. Follow-up of this study 
was for 21 days. The mean time of conversion of SARS-
CoV-2 positivity to negativity by pharyngeal RT-PCR was 
9.0 days, 9.1 days, and 9.3 days for the lopinavir/ritonavir, 
arbidol, and control group, respectively, and did not have 
any statistically significant difference. Also, the negative 
conversion at day 7 and day 14 showed no statistically 
significant difference between the groups. Furthermore, 
there was no statistical difference in the groups regarding 
clinical improvement, such as rate of antipyresis, rate of 
cough resolution, and rate of chest CT improvement at 
day 7 and at day 14. Of the lopinavir/ritonavir group eight 
patients, accounting for 23.5%, deteriorated to severe or 
critical clinical status in comparison to three, 8.6%, and 
two, 11.8%, participants in the arbidol and control group, 
respectively. In this study, the treatment of lopinavir/
ritonavir and arbidol as monotherapies did not shorten 
SARS-CoV-2 pharyngeal conversion, nor improve clini-
cal status. More patients in the lopinavir/ritonavir group 
progressed to more severe disease and had more side 
effects, such as nausea, vomiting, abdominal pain, and 
diarrhoea [55] (Table 2). But this study did not elaborate 
the initiation of treatment from symptom onset, which 
could have affected the results of this study.
For the treatment of COVID-19, the NIH recommends 
against the use of lopinavir/ritonavir and other HIV pro-
tease inhibitors in hospitalised and non-hospitalised 
patients according to the guideline update from February 
2021 [56]. The ERS supports this viewpoint and does not 
recommend lopinavir/ritonavir for hospitalised COVID-
19 patients [48]. Furthermore, a pharmacokinetic inves-
tigation in which eight COVID-19 patients received 
lopinavir/ritonavir in a dosage of 400  mg/100  mg orally 
two times per day for 3 to 10  days, concluded that, 
although plasma concentration of the drug in these 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 11 of 27Kröker and Tirzīte  Respiratory Research          (2021) 22:304  
patients were higher in comparison to HIV patients, the 
drug combination in this dosage could not reach plasma 
concentrations enough to inhibit the replication of SARS-
CoV-2 [57]. Also, in a recent scientific article, published 
in June 2020, researchers state that lopinavir and ritona-
vir had no effect on the inhibition of SARS-CoV-2’s main 
protease, or 3CLpro [58]. Therefore, lopinavir/ritonavir is 
not a good candidate for the treatment of COVID-19.
Remdesivir
Remdesivir is an adenosine analogue that has action 
against a broad spectrum of viruses. It is specifically 
known from clinical trials for the treatment of Ebola. 
By competing with adenosine triphosphate, remdesi-
vir inhibits RdRp and halts viral replication [59, 60]. 
This pharmacological agent has proven to have efficacy 
in  vitro and in animal studies with nonhuman primates 
against MERS-CoV [61, 62]. Remdesivir has also shown 
to have activity against other previous coronaviruses, 
including human coronaviruses, such as SARS-CoV, 
and zoonotic “pre-pandemic” coronaviruses, includ-
ing bat CoVs [63]. In  vitro activity against SARS-CoV-2 
at post-entry stages in Vero E6 cells has been stated 
[30]. Furthermore, antiviral efficacy of remdesivir in 
SARS-CoV-2-infected human nasal and bronchial air-
way epithelial cells has been proven [64]. These findings 
make remdesivir a promising agent in the fight against 
COVID-19.
In a multicentre study conducted in Hubei, China, a 
randomised, double-blinded, placebo-controlled trial 
was performed to detect the effectiveness and safety of 
remdesivir in severe, hospitalised COVID-19 patients. 
Patient with SARS-CoV-2 RT-PCR positivity, pneumo-
nia on chest imaging, a SpO2 equal to or beneath 94%, 
and in which the time between symptom onset and ran-
domisation was within 12 days were enrolled. 155 partici-
pants started treatment of intravenous remdesivir with 
a loading dose of 200  mg for the first day, followed by 
100 mg for 9 days. The control group with 78 participants 
received the same volume of placebo infusion for 10 days. 
Assessment of clinical improvement within 28 days was 
undertaken. The improvement of clinical status was 
defined as the reduction of two points in a six-point ordi-
nal scale or the discharge from the hospital. Between the 
groups there was no statistically significant difference 
in the time of clinical improvement. Thus, remdesivir 
was concluded to not have clinical benefits in this study. 
Adverse events occurred equally in both groups with 66% 
in the remdesivir and 64% in the placebo group, including 
hypoalbuminaemia, constipation, hypokalaemia, anae-
mia, and increased total bilirubin [65] (Table 3).
In the final report of the ACTT-1 trial, a randomised, 
double-blinded, placebo-controlled trial analysing 
remdesivir in hospitalised COVID-19 patients, partici-
pants from trial sites all over the world were enrolled 
to receive either remdesivir or a placebo. From 1114 
patients screened for eligibility, 541 participants were 
allocated to receive remdesivir in the same dosage as 
the beforementioned study for 10  days. The placebo 
group consisted of 521 participants and received the 
same volume of placebo for 10 days. The median time 
from onset of symptoms to randomisation was 9 days. 
90.1% of the patients enrolled had severe COVID-19, 
and the baseline characteristics did not differ between 
the groups. This study presented that the treatment 
with remdesivir expressed superiority in the time of 
recovery with a median time of 10 days in comparison 
to 15 days in the placebo group. This benefit of remde-
sivir was specifically seen in patients receiving base-
line low-flow oxygen therapy. The mortality by day 15 
was lower in the remdesivir group with 6.7% in com-
parison to 11.9% in the placebo group. The occurrence 
of serious adverse events was 24.6% in the remdesivir 
group, and 31.6% in the placebo group. These serious 
adverse events included respiratory failure occurring 
in 47 (8.8%) and 80 (15.5%) cases in the remdesivir 
and placebo group, respectively. The study concluded 
that remdesivir administered for 10  days had a ben-
efit in hospitalised patients with COVID-19, especially 
in patients receiving low-flow oxygen at baseline [66] 
(Table 3).
To evaluate the efficacy of different treatment dura-
tions of intravenous remdesivir in COVID-19 patients 
hospitalised in 55 hospitals all over the world, a ran-
domised, open-label clinical trial assigned 200 patients 
to receive remdesivir 200 mg on the first day and 100 mg 
per day on the following days for a total amount of 5 
days, and 197 patients to receive the same dosing for a 
total of 10  days. Eligible participants were those with 
PCR-confirmed SARS-CoV-2 infection not beyond 4 
days before randomisation, imaging-confirmed pneu-
monia, and patients with a SpO2 of not more than 94% 
or receiving supplemental oxygen. Patients with more 
severe baseline status were allocated to the longer-course 
group. After 14 days, a clinical improvement, defined as 
a change of two points on a seven-point ordinal scale, 
was seen in 65% of the 5-day course versus in 54% of the 
10-day course group. After the baseline differences were 
adjusted, the two groups appeared to have similar results 
in time to clinical improvement, recovery, and death. The 
study did not conclude a significant difference of potency 
of the two administration courses in severe COVID-19 
patients who did not require mechanical ventilation. But 
of the patients that developed a disease course requiring 
mechanical ventilation, a 10-day course of remdesivir was 
more beneficial [67] (Table  3). However, the complete 
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efficacy of remdesivir cannot be ascertained in this study 
due to the lack of a control group.
The previous clinical trials concentrated on the effi-
cacy of remdesivir in severe COVID-19 patients. But 
a randomised, open-label trial was concerned with the 
efficacy of remdesivir in moderately diseased COVID-19 
patients. Eligible for this trial were hospitalised patients 
with PCR-confirmed SARS-CoV-2 infection, with pul-
monary infiltrates and a SpO2 above 94% on room air. 
Remdesivir was dosed intravenously 200 mg on the first 
day and 100 mg once per day for following days. Of 596 
patients randomised, 197 participants were grouped to 
receive remdesivir for 10  days, 199 for 5 days, and 200 
patients were allocated to the standard care group. After 
11 days, the odds of better clinical status were higher in 
the 5-day group compared to the standard care group. 
These findings were statistically significant, but the study 
concluded uncertainty if this difference could be clini-
cally important. For the 10-day group there was no sig-
nificant difference to the standard care group in clinical 
status distribution after 11  days. Furthermore, adverse 
events, such as headache, nausea, and hypokalaemia 
were more present in patients receiving remdesivir. The 
difference in the occurrence of adverse events, was only 
statistically significant between the 10-day and standard 
care group, but not between the 5-day and the standard 
care group. Serious adverse events were more commonly 
found in the standard care group with a larger difference 
between the standard care and 5-day course group, than 
between standard care and 10-day course group. The 
occurrence of death after 28 days was equally distributed 
between the groups and had no linkage to the treatment 
with remdesivir [68] (Table 3). This study provided infor-
mation on the efficacy of remdesivir given for 5 days on 
moderately diseased COVID-19 patients, but the benefit 
is questionable.
In the recent report of the WHO solidarity trials from 
December 2020, remdesivir as well as the other tested 
repurposed antiviral agents, hydroxychloroquine, lopi-
navir and interferon beta-1a, did not reduce mortal-
ity, initiation of ventilation, nor hospital duration in 
patients hospitalised with COVID-19. In this open-label 
randomised clinical trial, in-hospital mortality of 2743 
patients receiving remdesivir was 12.5% in comparison 
to 12.7% of 2708 patients receiving standard of care. 67% 
of patients in both the remdesivir and the control arm 
were receiving supplemental oxygen at trial entry. 24% 
of the remdesivir patients were receiving no supplemen-
tal oxygen at entry, whereas 25% in the control group. 
Participant characteristics of mechanical ventilation at 
entry was also equally distributed with 9% in each study 
group. Furthermore, there was no reduction of initiation 
of ventilation among patients not already on ventilation 
with remdesivir in comparison to standard of care [69] 
(Table 3).
The efficacy of remdesivir in the pharmacological 
treatment of COVID-19 remains questionable. Nev-
ertheless, following the February 2021 update of the 
NIH COVID-19 Treatment Guidelines, remdesivir 
monotherapy is recommended with moderate rating to 
hospitalised COVID-19 patients requiring minimal sup-
plemental oxygen. The combination of remdesivir with 
dexamethasone is recommended with moderate rating 
based on expert opinion to hospitalised patients requir-
ing increased amounts of supplemental oxygen and who 
require oxygen delivery through high-flow devices or 
non-invasive ventilation. For hospitalised patients with 
COVID-19 who do not require supplemental oxygen the 
treatment with remdesivir is lacking data [70]. The ERS 
does not recommend remdesivir for hospitalised patients 
with COVID-19 requiring mechanical ventilation. Due to 
lack of reported benefits of randomised trials, the ERS is 
not making a recommendation for nor against the use of 
remdesivir in patients hospitalised with COVID-19 and 
not requiring invasive mechanical ventilation as of March 
2021 [48].
Pharmacological agents with immunomodulatory 
properties
Tocilizumab
The cytokine storm plays an important role in the patho-
genesis of severe COVID-19. A significant component of 
this cytokine storm, or cytokine release syndrome (CRS), 
is IL-6. Tocilizumab is a recombinant humanised mono-
clonal antibody that binds soluble and membrane-bound 
IL-6 receptors and inhibits its signal transduction. This 
pharmacological agent is used in the treatment of rheu-
matoid arthritis, as well as CRS and SIRS. These immu-
nomodulatory features of tocilizumab are thought to 
alleviate the severity of symptoms in COVID-19 patients 
experiencing a CRS [71, 72].
In a retrospective, observational cohort of 544 patients 
with severe COVID-19 pneumonia performed in Italy, 
the administration of tocilizumab appeared to reduce 
the risk for invasive mechanical ventilation and death. 
365 of these participants were receiving standard care 
alone, including the use of supplemental oxygen ther-
apy, hydroxychloroquine, azithromycin, lopinavir/rito-
navir or darunavir-cobicistat, and low-molecular weight 
heparin, if indicated by a physician. 179 participants 
received tocilizumab additionally to standard care. 88 of 
these 179 participants received intravenous tocilizumab 
8 mg per kilogram of body weight with a maximum of 
800 mg, twice, 12 h apart. 91 participants received toci-
lizumab subcutaneously, 162 mg in two doses that were 
administered at the same time once. As this study was 
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not randomised, patients with more severe baseline char-
acteristics were allocated to receive tocilizumab. After 
adjustment of these characteristics and the comparison 
between the groups, tocilizumab, in both administration 
routes, correlated with reduced risk of mechanical venti-
lation and death. On the other hand, tocilizumab use was 
also associated with a higher prevalence of new infec-
tions in comparison to standard care. This study declared 
a possible benefit of tocilizumab in severe COVID-19 
patients and recommended a confirmation of these find-
ings with randomised clinical trials [73] (Table 4).
Another observational cohort with 154 severe COVID-
19 patients needing mechanical ventilation supports the 
use of tocilizumab as it correlated with improvement of 
survival. In comparison to a control group, the group 
receiving tocilizumab experienced a reduction of 45% 
in hazard of death. However, tocilizumab use was more 
frequently associated with superinfections, although, the 
case fatality rate between tocilizumab patients with or 
without superinfections was not significantly different 
[74] (Table 4).
In a randomised, doubled-blinded, placebo-controlled 
phase 3 trial, tocilizumab was evaluated for its safety 
and efficacy in COVID-19 patients. Eligibility criteria 
for enrolment included hospitalisation for COVID-19 
pneumonia confirmed by PCR and radiographic imag-
ing and SpO2 of less than 94% on ambient air breathing. 
Patients receiving continuous positive airway pressure, 
bilevel positive airway pressure, or mechanical venti-
lation were excluded from the trial. 249 patients were 
allocated to the tocilizumab group, receiving 8 mg per 
kilogram of body weight of tocilizumab in one or two 
doses intravenously, in addition to standard care accord-
ing to local guidelines which could include antiviral treat-
ment, systemic glucocorticoids, and supportive care. 128 
patients were grouped to receive placebo in addition to 
standard care. Characteristics of the demographics and 
the disease of the patients at baseline were equally dis-
tributed among the two groups. In the assessment of the 
primary outcome of mechanical ventilation or death by 
day 28, the use of tocilizumab expressed a significant 
benefit in comparison to placebo. 12.0% of the tocili-
zumab group and 19.3% of the placebo group required 
mechanical ventilation or had died by day 28. Secondary 
outcomes of median times to hospital discharge or readi-
ness for discharge, to improvement of clinical status, and 
to clinical failure were similar among the groups. Mor-
tality from any cause by day 28 was 10.4% in the tocili-
zumab and 8.6% in the placebo group. The study suggests 
a benefit of tocilizumab in hospitalised patients with 
COVID-19 pneumonia with hypoxia and not receiving 
mechanical ventilation at treatment start and, possibly, 
an additional beneficial effect of tocilizumab to antiviral 
or corticosteroid therapy. In this trial, tocilizumab could 
reduce the likelihood of disease progression to the need 
of mechanical ventilation or death, but it did not improve 
survival [75] (Table 4).
In a preliminary report of the open-label randomised 
trial REMAP-CAP, the use of tocilizumab and sarilumab, 
both IL-6 receptor antagonists, in critically ill COVID-
19 patients receiving respiratory or cardiovascular 
organ support was superior to standard of care. In this 
study, 353 patients were designated to the tocilizumab 
group, receiving the drug in a dosage of 8 mg per kilo-
gram of body weight as an intravenous infusion over 1 
h with a possible additional dosage 12 to 24  h later. 48 
patients were allocated to receive sarilumab in a dosage 
of 400 mg, administered once as an intravenous infusion. 
402 patients were assorted to the control group receiving 
standard care including corticosteroid therapy in more 
than 80% of the patients. Randomisation of COVID-19 
patients occurred within 24 h of organ support in inten-
sive care units and baseline characteristics of the patients 
were equally distributed across the groups. The results 
of the primary outcome of organ support-free days up to 
day 21 were 10 in the tocilizumab group, 11 in the sari-
lumab, and 0 in the control group. The use of tocilizumab 
and sarilumab was also associated with shorter time to 
clinical improvement and reduced in-hospital mortality 
in comparison to the control [76] (Table 4).
From the March 2021 statement of the NIH COVID-19 
Treatment Guidelines, the use of tocilizumab in combi-
nation with dexamethasone is recommended in hospi-
talised patients with COVID-19 and rapid respiratory 
decompensation. This includes patients admitted to the 
ICU within 24 h and requiring invasive mechanical ven-
tilation, non-invasive ventilation, and oxygen through 
high-flow nasal canula, and hospitalised non-ICU 
patients whose oxygen need is rapidly increasing requir-
ing non-invasive ventilation or oxygen through high-
flow nasal canula [77]. The ERS suggest the use of IL-6 
receptor antagonist monoclonal antibodies in COVID-19 
patients in the need of oxygen or ventilatory support. It is 
noted that the therapy with corticosteroids should have 
already been completed or initiated in these patients if 
not contraindicated. The ERS guidelines also note ben-
efits of treatment start within 24 h of ventilatory support 
and in patients with high risk to progress to ventilatory 
support despite corticosteroid therapy [48].
Corticosteroids
Another immunomodulatory option for the potential 
treatment of severe COVID-19 is the administration of 
corticosteroids. Although the use of corticosteroids in 
viral infection is questionable, their anti-inflammatory 
and antifibrotic actions could have beneficial effects on 
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pneumonia, ARDS, and septic shock [78]. Previous stud-
ies evaluating corticosteroids in ARDS and septic shock 
patients concluded that corticosteroids could reduce 
mortality and duration of mechanical ventilation [78–
81]. These insights give hope in the treatment of severe 
and mechanically ventilated COVID-19 patients with 
corticosteroids to wean the patients off from respiratory 
support and to reduce mortality.
In a report of the results of a controlled, open-label 
trial that is part of the RECOVERY trial in the United 
Kingdom, 6425 eligible patients were randomised 
to receive either usual care or usual care with addi-
tional dexamethasone. 2104 patients were allocated to 
receive dexamethasone, 6 mg once per day for 10  days 
or until hospital discharge administered orally or intra-
venously. 4321 patients were grouped to receive usual 
care. Patients that were eligible for this trial were those 
with clinically suspected or laboratory confirmed SARS-
CoV-2 infection and had no contraindications for the 
use of corticosteroids. After a primary outcome assess-
ment of 28-day mortality, the group receiving mechanical 
ventilation or just supplemental oxygen therapy with-
out mechanical ventilation at the time of randomisation 
in the dexamethasone group had a lower mortality rate 
than those in the usual care group. For patients that did 
not need respiratory support at the time of randomisa-
tion, the use of dexamethasone was not significantly 
beneficial in comparison to usual care. Furthermore, the 
reduction of mortality was experienced more in individu-
als that had symptoms for more than 7 days but not in 
those with recent symptom onset which possibly corre-
lates to the prevalence of inflammatory lung damage. In 
this study, the use of dexamethasone was associated with 
lower risk of patients receiving oxygen to deteriorate to 
invasive mechanical ventilation and a greater likelihood 
of patients already on invasive mechanical ventilation to 
successful weaning [82] (Table 5). The RECOVERY trial 
proved a benefit of low-dose dexamethasone in mechani-
cally ventilated and oxygen-needing, not mechanically 
ventilated COVID-19 patients.
The CoDEX multicentre, randomised, open-label clini-
cal trial in Brazil supports the findings of the RECOVERY 
trial. This trial enrolled 299 ICU patients with confirmed 
or suspected COVID-19 with moderate to severe ARDS. 
Randomisation allocated 148 patients to receive standard 
care and 151 patients to receive standard care with dexa-
methasone, intravenously 20 mg per day for 5 days, fol-
lowed by 10 mg per day for another 5 days or, if occurring 
earlier, until discharge from the intensive care unit. After 
a follow-up of 28 days, the dexamethasone group had a 
statistically significant longer time of days being free 
from mechanical ventilation and being alive with a mean 
time of 6.6 days in comparison to 4.0 days in the standard 
care group. Also, the dexamethasone group had a signifi-
cantly lower mean Sequential Organ Failure Assessment 
(SOFA) score than the comparison group. Secondary 
outcome assessments, such as mortality of all causes, 
ICU-free days, and duration of mechanical ventilation 
after 28 days, as well as clinical status on a six-point ordi-
nal scale at day 15, had no statistically significant differ-
ence between the groups. Furthermore, the occurrence 
of secondary infections, adverse events, and insulin need 
for glucose control was similar between the groups [83] 
(Table 5). This trial was terminated early due to the find-
ings of the previously mentioned trial and, thus, did not 
reach their goal sample size, which could explain the lack 
of positive secondary outcome confirmation. Neverthe-
less, the CoDEX trial provided evidence on the benefit 
of high-dose dexamethasone in COVID-19 patients with 
moderate to severe ARDS.
In a multicentre, randomised, double-blinded clinical 
trial in France, the treatment efficacy of low-dose hydro-
cortisone was evaluated in critically ill ICU patients with 
acute respiratory failure due to COVID-19. 76 patients 
were assigned to receive hydrocortisone, administered 
intravenously, 200  mg per day for 7 days, followed by 
100 mg per day for the next 4 days, and then 50 mg per 
day for another 3 days. 73 participants received a placebo 
of saline solution. The primary outcome assessed was the 
treatment failure at day 21, which was determined as the 
occurrence of death, continued mechanical ventilation, 
or persistence of high-flow oxygen therapy. The hydro-
cortisone group had comparatively less treatment failure 
events with 42.1%, versus 50.7% in the placebo group. 
However, this difference was marked as not statistically 
significant. Also, there was no statistically significant dif-
ference in the evaluation of secondary outcomes, includ-
ing the need of tracheal intubation in non-intubated 
patients at time of randomisation, the need of prone 
positioning, ECMO, or nitric oxide inhalation, the ratio 
of arterial oxygen partial pressure to fractional inspired 
oxygen  (PaO2:FIO2) at days 1 to 7 and on days 14 and 21, 
and the post hoc analysis of cumulative proportions of 
nosocomial infections for up to day 28. This study con-
cluded no statistically significant benefit of low-dose 
hydrocortisone in critically ill COVID-19 patients with 
acute respiratory failure [84] (Table 5). Although this trial 
had good potential in delivering significant information 
due to its placebo-controlled layout, it was also termi-
nated early because of the findings of the RECOVERY 
trial and had therefore not reached their target sample 
size which could have affected the results of the study. 
Similar results were presented by the REMAP-CAP trial 
on low-dose hydrocortisone in intensive care COVID-
19 patients, but the study was also terminated early [85] 
(Table 5).
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In the Brazilian randomised, double-blinded, phase 
IIb, placebo-controlled trial, named Metcovid, the effi-
cacy of a short course of high-dose methylprednisolone 
was investigated in patients hospitalised for suspected 
COVID-19. Patients that were enrolled were adults 
that had a SpO2 of 94% or less, those receiving sup-
plementary oxygen therapy, or those receiving invasive 
mechanical ventilation and had a suspected or con-
firmed SARS-CoV-2 infection. RT-PCR confirmation 
of SARS-CoV-2 infection was presented in 81.3% of the 
patients. 194 participants received 0.5 mg per kilogram 
of intravenous methylprednisolone two times daily for 5 
days, whereas 199 patients received a placebo of saline 
solution. The median time from disease onset to ran-
domisation was 13 days in both groups. The assessment 
of the primary outcome of mortality at day 28 dem-
onstrated equal results between the groups, although 
patients above the age of 60 in the methylprednisolone 
group appeared to have lower mortality and benefitted 
from corticosteroid use. The patients in this age group 
had generally higher C-reactive protein levels and 
more distinct systemic inflammation [86] (Table 5). In 
comparison to the results of the RECOVERY trial, this 
study could not declare a definite benefit of corticoster-
oids in the treatment of the enrolled patients. However, 
the treatment courses were different between these tri-
als and patients in the Metcovid trial were treated with 
corticosteroids only for 5 days in comparison to 10 days 
in the RECOVERY trial.
From the February 2021 update of the COVID-19 
Treatment Guidelines, the Panel strongly recommends 
dexamethasone for hospitalised COVID-19 patients 
who require supplemental oxygen through high-flow 
devices or non-invasive ventilation. A combination 
with remdesivir is also mentioned as a treatment option 
for these patients. Dexamethasone is also strongly 
recommended for hospitalised patients on invasive 
ventilation or ECMO. For hospitalised patients who 
require increasing amounts of supplemental oxygen 
not through a high-flow device, non-invasive ventila-
tion, invasive mechanical ventilation, or ECMO the use 
of dexamethasone can optionally be added to the treat-
ment of remdesivir or can be administered as mono-
therapy if a combination with remdesivir is not feasible. 
Furthermore, the Panel strongly recommends against 
the use of dexamethasone for hospitalised COVID-
19 patients who do not need supplemental oxygen 
and to non-hospitalised, mild to moderate COVID-19 
patients. Recommended alternatives for dexametha-
sone, if not available, are prednisone, methylpredniso-
lone, and hydrocortisone [70]. The ERS supports this 
viewpoint by strongly suggesting systemic corticoster-
oids to patients who are hospitalised for COVID-19 




COVID-19 has potential in causing severe inflamma-
tion leading to cytokine storm, SIRS, and multiple organ 
failure. These factors, as well as the disrupted alveolar-
endothelial barrier, possible infection of endothelial 
cells by the virus, and additional factors, such as immo-
bilisation and comorbidities of patients, give rise to an 
increased risk of thromboembolic complications [21–23].
ARDS is an important component of the disease patho-
genesis of COVID-19. A previous prospective pilot study, 
published in 2016, already linked ARDS with coagu-
lopathy [87]. Mechanically ventilated ARDS patients 
had significantly higher median plasma concentrations 
of tissue factor and plasminogen activator inhibitor-1 
at day 7 of ICU treatment in comparison to non-ARDS 
patients. Pathological investigations of deceased COVID-
19 patients support the theory of hypercoagulation 
by the findings of increased incidences of pulmonary 
microthrombi [88]. Furthermore, in pulmonary autop-
sies of ARDS patients who were infected with COVID-
19 in comparison to influenza H1N1-associated ARDS 
patients, lungs from both groups presented with dif-
fuse alveolar damage and infiltrating perivascular lym-
phocytes, but the COVID-19 affected lungs had more 
severe endothelial injury with intracellular virus, dis-
rupted endothelial cell membranes, widespread vascular 
thrombosis with microangiopathy, occlusion of alveolar 
capillaries, and significantly more new vessels through 
intussusceptive angiogenesis [89].
A retrospective cohort study in Wuhan, China dem-
onstrated that in 183 patients admitted to the hospi-
tal between January to February 2020 with confirmed 
COVID-19 pneumonia, non-survivors presented signifi-
cantly higher D-dimer and fibrin degradation products, 
and longer prothrombin time at the time of admission in 
comparison to survivors. These factors correlated signifi-
cantly with disease prognosis. 71.4% of the non-survivors 
also met criteria for overt disseminated intravascular 
coagulation (DIC) according to the International Society 
on Thrombosis and Haemostasis diagnostic criteria [90]. 
The association of these abnormal coagulation markers 
with disease severity, ICU-admission, and mortality in 
COVID-19 patients has been supported by several cohort 
studies in China and in the United States [16, 91–93].
In a Chinese retrospective cohort analysis of 449 severe 
COVID-19 patient, 99 patients received concurrent hep-
arin treatment for 7 days. 94 of these 99 patients received 
low molecular weight heparin (LMWH). Although, the 
28-day mortality was not different between patients 
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receiving heparin and those who did not, a benefit was 
experienced in patients with sepsis-induced coagulopa-
thy score of four and more, and in patients with markedly 
increased D-dimers of more than six-fold of the upper 
limit of normal. These patients had a significantly lower 
28-day mortality when heparin was used [94].
An Irish prospective cohort study suggests that the 
coagulopathy occurring in COVID-19 in early stages is 
rather distinct from typical DIC and that the diffuse pul-
monary bilateral inflammation in COVID-19 leads to 
a pulmonary-specific vasculopathy, termed pulmonary 
intravascular coagulopathy (PIC). In the mainly Cau-
casian population of this cohort, a prophylactic dose of 
LMWH was administered concurrently to the study and 
no systemic DIC was reported. The study additionally 
proposes that the administration of prophylactic dose 
LMWH does not have a significant impact on increas-
ing D-dimer levels and that further randomised con-
trolled studies should evaluate more intensive dosing 
strategies in severe COVID-19 patients with PIC pres-
entation [95]. This suggestion is advocated by a French 
prospective cohort in which 150 patients with COVID-
19 ARDS were assessed for thrombotic risk in compari-
son to non-COVID-19 ARDS patients. None of the 150 
COVID-19 patients developed overt DIC, but despite 
the administration of prophylactic or therapeutic anti-
coagulation, thromboembolic complications were highly 
prevalent and significantly more than in non-COVID-19 
ARDS patients. The most common thromboembolic 
event was pulmonary embolism, occurring in 16.7% of 
the 150 COVID-19 patients [96]. These findings suggest 
that close monitoring of severe COVID-19 patients with 
ARDS for coagulation markers and treatment of devel-
oping PIC with higher dose anticoagulation should be 
evaluated in randomised clinical trials for the potential 
decrease of disease mortality.
As of March 2021, The NIH cannot provide verified 
recommendations for anticoagulative therapy strategies 
in COVID-19 patients due to the lack of data from ran-
domised trials. Nevertheless, based on expert opinion, 
the Panel strongly recommends venous thromboembo-
lism prophylaxis for hospitalised COVID-19 patients as 
per the standard of care for other hospitalised patients. 
At the time of this review, the use of thrombolytics or 
increased doses for venous thromboembolism prophy-
laxis in COVID-19 patients outside of clinical trials is 
neither recommended for nor against. The treatment of 
COVID-19 patients with thromboembolic events should 
be commenced with therapeutic anticoagulative therapy 
as per the standard of care for non-COVID-19 patients. 
Those COVID-19 patients requiring ECMO or continu-
ous renal replacement therapy, and those with catheter 
or extracorporeal filter thrombosis should be treated 
with antithrombotic therapy as per standard institutional 
protocol for non-COVID-19 patients [97]. The ERS sup-
ports the recommendation of offering a form of antico-
agulation to hospitalised COVID-19 patients but are not 
able to make a recommendation regarding dose or type 
of anticoagulative therapy due to lack of data as of March 
2021 [48].
Discussion
The hurry in finding a cure for COVID-19 has brought 
problems with the acceptance of some clinical trials due 
to arguments about methodological incorrectness. The 
lack of a clear consensus on primary and secondary out-
comes and endpoints, as well as inclusion criteria for 
enrolment of clinical trials testing for pharmacological 
treatment of COVID-19 make it difficult to interpret and 
compare the results. Furthermore, whereas clinical tri-
als in randomised, blinded, placebo-controlled fashion 
provide the little biased information of novel treatment 
strategies, these trial goals were not always feasible dur-
ing the pandemic. What resulted in was a mixture of 
different approaches to find pharmacological agents for 
COVID-19 treatment that were not always presented 
without their limitations.
In total, 97 references were studied and used to conduct 
this research paper. Due to the vast number of published 
articles on this new topic, not all research papers found 
in the utilised databases could be taken into considera-
tion. Articles prioritised for selection were those that 
were most recently published and peer reviewed by the 
time of the conduction of this literature review. Research 
papers providing information on COVID-19 pharmaco-
logical treatment that had not been peer reviewed, yet, 
had to be excluded.
In vitro analyses of SARS-CoV-2, as well as previous 
studies of SARS and MERS treatment became guides for 
the direction of possible COVID-19 treatment. Taken by 
the example of the in  vitro analyses of chloroquine and 
hydroxychloroquine, it appears to be indisputable that 
investigations in SARS-CoV-2-infected human airway 
epithelial cells should have led the discussion before the 
proposal of clinical trials and that human airway epithe-
lial cells for SARS-CoV-2 in  vitro drug analyses should 
become standard procedure [45, 46].
The results of clinical trials surrounded with the topic 
of drug treatment of COVID-19 with chloroquine or 
hydroxychloroquine with or without azithromycin pre-
cipitated the most controversy. Whereas a handful of 
clinical trials advocated the use of chloroquine in the 
treatment of COVID-19, other trials reported no proven 
benefit of chloroquine in COVID-19 patients [33–35]. 
Hydroxychloroquine for the treatment of mild to mod-
erate COVID-19, as well as the observations of risk of 
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intubation or death in SARS-CoV-2-positive, hospital-
ised patients did not conclude a benefit of hydroxychlo-
roquine treatment in COVID-19 patients [36, 37]. The 
combination of hydroxychloroquine and azithromycin 
for the use of SARS-CoV-2 viral load reduction has been 
advocated by a French clinical trial lead by Gautret and 
colleagues [38]. However, the results of this study and 
the effect of the drug combination on patients’ viral load 
have been opposed by critics and negated by studies [39–
41]. Furthermore, no effect of clinical improvement was 
ascribed to the use of hydroxychloroquine and azithro-
mycin in mild to moderate COVID-19 patients [42]. As 
a possible postexposure prophylaxis, hydroxychloroquine 
has not proven to have sufficient effect on a population 
of mainly health care workers [43]. Both chloroquine and 
hydroxychloroquine, especially in high dosing and in the 
combination with azithromycin, have potential in caus-
ing cardiac side effects and prolonged QTc, giving rise 
to a significant risk in causing life-threatening arrhyth-
mia [33, 41, 42, 46]. Considering the given data, neither 
chloroquine, nor hydroxychloroquine with or without 
azithromycin present clear proven clinical benefit for the 
treatment of COVID-19.
The drug combination lopinavir/ritonavir has also 
not presented convincing efficacy in the treatment of 
COVID-19. While an early administration of lopinavir/
ritonavir within 10 days of symptom onset, as observed 
in an observational cohort, could potentially decrease 
time of SARS-CoV-2 shedding, randomised controlled 
trials could not present efficacy in improving clinical 
status nor in shortening pharyngeal viral detectability 
in COVID-19 patients [52, 54, 55]. Moreover, a pharma-
cokinetic analysis of lopinavir/ritonavir in standard dos-
ing concluded inefficient plasma concentrations for the 
inhibition of SARS-CoV-2 replication [57]. Given the 
evidence, lopinavir/ritonavir appears to be ineffective in 
treating SARS-CoV-2 infections.
Randomised controlled trials provide proof on 
the efficacy and safety of remdesivir in hospitalised 
COVID-19 patients requiring supplemental oxygen 
therapy [66–68]. Specifically, the ACTT-1 trial supports 
the use of remdesivir in COVID-19 patients receiving 
low-flow oxygen therapy as it expressed superiority in 
the time of recovery in comparison to the control [66]. 
On the other hand, the results of the WHO Solidar-
ity trial did not present clinical benefits of remdesivir 
treatment reducing mortality, initiation of ventilation, 
nor hospital duration in patients hospitalised with 
COVID-19 [69]. At the time of the conduction of this 
research paper, the NIH recommends remdesivir mon-
otherapy only in patients hospitalised with COVID-
19 who require minimal supplemental oxygen [70]. In 
contrary, the ERS makes no recommendation on the 
treatment of hospitalised patients with COVID-19 
who do not require invasive mechanical ventilation 
[48]. Results of further randomised trials are needed 
to support the results of the ACTT-1 trial. Also, more 
trials should be conducted on the efficacy and safety of 
remdesivir and dexamethasone combination therapy 
in COVID-19 patients. Remdesivir is the first and, as 
of the time of this review, the only antiviral agent that 
is recommended for the clinical treatment of COVID-
19 patients. As the use of remdesivir is becoming of 
more clinical importance during the COVID-19 pan-
demic, clinical trials investigating possible side effects 
of the usage of remdesivir in COVID-19 patients, such 
as hypokalaemia, are of utter importance and should as 
well be proposed.
Drugs acting against the cytokine storm of COVID-
19 have good potential in decreasing the mortality in 
theory. Following the recent results of randomised clini-
cal trials, tocilizumab seems to be a promising agent in 
the pharmacological treatment of COVID-19 by reduc-
ing the likelihood of disease progression, time to clini-
cal improvement, and mortality, specifically in patients 
admitted to ICU within 24 h on organ support [75, 76]. 
The NIH as well as the ERS have spoken out about a 
treatment recommendation of COVID-19 including toci-
lizumab [48, 77]. Future research should focus on the 
benefits of a possible drug combination with dexametha-
sone in severe COVID-19 patients and the optimal tim-
ing and target group of tocilizumab initiation.
The RECOVERY trial has delivered positive results 
on the clinical efficacy of low-dose dexamethasone in 
mechanically ventilated and non-mechanically venti-
lated, but supplemental oxygen requiring COVID-19 
patients [82]. Systemic corticosteroids, specifically dexa-
methasone, are the treatment modality with the most 
evidence on the efficacy against severe COVID-19 and 
are included in the treatment guidelines of the NIH and 
ERS [48, 70].
Thromboembolic events are serious complications of 
severe COVID-19 cases [20]. As of March 2021, throm-
boprophylaxis and thromboembolic treatment are rec-
ommended for COVID-19 patients as per standard 
protocol for regular ward or intensive care patients [97]. 
Further research in the areas of the COVID-19-specific 
coagulopathy and testing of higher dose anticoagula-
tion, possibly in combination with immunotherapy, in 
randomised controlled trials is necessary to gain data 
about possible improvements of mortality rates in severe 
COVID-19 cases.
Furthermore, the spread of SARS-CoV-2 and the 
search of its origin has put attention to the topical-
ity of zoonotic transmissions of infectious diseases. 
By spending more research on the exact origin of 
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SARS-CoV-2 and the prevention of zoonotic transmis-
sions, future epidemic- or pandemic-causing infectious 
diseases could potentially be prevented, possibly saving 
future lives [9].
Conclusions
In conclusion, the most beneficial pharmacological agent 
for the treatment of COVID-19 are corticosteroids, espe-
cially dexamethasone, for the treatment of mechanically 
ventilated COVID-19 patients. Other promising agents 
are remdesivir for the treatment of patients with COVID-
19 pneumonia requiring minimal supplemental oxygen 
therapy, and IL-6 receptor antagonist monoclonal anti-
bodies in severe COVID-19. Lopinavir/ritonavir, as well 
as chloroquine or hydroxychloroquine with or without 
azithromycin demonstrate the least efficacy in the treat-
ment of COVID-19. The clinical benefits of the treatment 
of a COVID-19-specific coagulopathy with increased 
dosing of anticoagulation need further research and con-
firmation of randomised controlled trials.
The COVID-19 pandemic, as devastating as it is, is 
teaching humanity an important lesson in dealing with 
crises. Instead of getting defeated by this pandemic, 
we need to evaluate what we have done correctly and 
admit what we have done wrong to be prepared for the 
next crisis.
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